Tirzepatide combination therapy in psoriasis patients achieved enhanced skin clearance alongside substantial weight loss and reduced psoriatic arthritis risk—a trifecta rarely delivered by conventional biologics. In hidradenitis suppurativa and atopic dermatitis, GLP-1 receptor agonists (GLP-1RAs) reduced cardiometabolic complications and systemic disease burden independent of direct anti-inflammatory mechanisms, according to evidence aggregated from clinical trials, observational studies, and real-world analyses.
The framing here matters enormously. Dermatologists have long treated psoriasis, hidradenitis suppurativa, and atopic dermatitis as skin-primary diseases, deploying IL-17, IL-23, and JAK inhibitors with impressive lesion-clearing results but leaving metabolic syndrome, visceral adiposity, and cardiovascular risk largely unaddressed. GLP-1RAs invert that logic—their primary lever is systemic immunometabolic recalibration, with skin improvement partly downstream of adipokine normalization, reduced TNF-α, and improved insulin sensitivity. This is conceptually significant: it positions obesity-driven chronic inflammation as a modifiable upstream driver rather than a passive comorbidity.
That said, this is a narrative review synthesizing heterogeneous evidence, not a meta-analysis of randomized controlled trials. Effect sizes, durability, and head-to-head comparisons with established biologics remain poorly defined. Tirzepatide's dual GIP/GLP-1 agonism makes mechanistic attribution messy. Real-world analyses carry confounding risks. For clinicians managing metabolically complex dermatology patients, GLP-1RAs represent a genuinely compelling adjunct—but primary therapy displacement awaits prospective trial validation.